Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Silexion Therapeutics ( (SLXN) ).
Silexion Therapeutics announced the completion of a 1-for-15 reverse share split of its ordinary shares, approved by shareholders at the 2025 Annual General Meeting on July 14, 2025. The reverse split, effective after the close of business on July 28, 2025, reduces the number of issued and outstanding shares while maintaining the authorized share capital at $20,000, and the shares will trade on a split-adjusted basis under the ticker symbol ‘SLXN’ starting July 29, 2025.
The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Average Trading Volume: 729,299
Technical Sentiment Signal: Sell
Current Market Cap: $7.61M
For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.